Paediatric antiretroviral (ARV) medicines: market and supply update
Information on ARVs, highlighting product supply, demand and market developments.
HIV continues to be a major global public health issue, having claimed to date more than 32 million lives, according to the World Health Organization. Only 51 per cent of all HIV-exposed infants are tested for HIV and only 55 per cent of all children under 14 years of age, and even fewer adolescents living with HIV, are on treatment.
This note provides information on paediatric antiretroviral (ARV) medicines. Even though new, more effective, and better tolerated ARV options are now available for adults, optimized treatment options for children lag significantly behind and cost more than to treat an adult. UNICEF seeks to consolidate this fragmented market as much as possible, minimize supply insecurity, improve affordability, as well as to extend efforts to support product alignment with WHO treatment guidelines.